Table 1. Tumor immunotherapy classification.
| Category | Agent | Approved for | |
|---|---|---|---|
| Mechanism | Drug name | ||
| ICIs | Anti-PD-1 mAb | Pembrolizumab (Keytruda) | Non-small cell lung cancer (NSCLC), metastatic melanoma |
| Nivolumab (Opdivo) | |||
| Anti-PD-L1 mAb | Atezolizumab (Tecentriq) | NSCLC, bladder cancer | |
| Avelumab (Bavencio) | Urothelial carcinoma, Merkel cell carcinoma | ||
| Durvalumab (Imfinzi) | Urothelial carcinoma | ||
| Anti-CTLA-4 mAb | Ipilimumab (Yervoy) | Metastatic melanoma | |
| Anti-LAG-3 mAb | Relatlimab | Melanoma | |
| Therapeutic antibody | Rituximab | Non-Hodgkin’s Lymphoma | |
| Trastuzumab | Breast cancer | ||
| Panitumumab | Colorectal cancer | ||
| Cancer vaccines | Sipuleucel-T vaccine | Prostatic cancer | |
| Cervical cancer vaccine | Cervical cancer | ||
| Cell therapy (adoptive T cell transfer, ACT) | Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) therapy | Yescarta (AxicabtageneCiloleucel, KTE-C10) | Acute lymphocytic leukemia (ALL) |
| Small molecule inhibitors | Indoleamie 2,3-dioxyge (IDO) inhibitor | Epacadostat | Melanoma |
| Immune system modulators | Cytokine therapy (IL-2, INF), immune adjuvants (BCG) and short peptides (thymus method) | Metastatic renal carcinoma, malignant melanoma | |